Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caleb Cheng

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapyYi Bao, Yuanyuan Qiao, Jae Eun Choi, et al.
Cell Reports. Medicine|March 25, 2026
Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumorsYizhi Cao, Caleb Cheng, Yitong Yin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2023
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory responseYuanyuan Qiao, Jesse W Wotring, Yang Zheng, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancerCaleb Cheng, Jing Hu, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Nature|April 24, 2025
Targeting PIKfyve-driven lipid metabolism in pancreatic cancerCaleb Cheng, Jing Hu, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapyYi Bao, Yuanyuan Qiao, Jae Eun Choi, et al.
Cell Reports. Medicine|March 25, 2026
Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumorsYizhi Cao, Caleb Cheng, Yitong Yin, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2023
Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory responseYuanyuan Qiao, Jesse W Wotring, Yang Zheng, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancerCaleb Cheng, Jing Hu, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 1, 2024
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancerTongchen He, Caleb Cheng, Yuanyuan Qiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinomaJean Ching-Yi Tien, Yali Zhai, Rong Wu, et al.
Nature|April 24, 2025
Targeting PIKfyve-driven lipid metabolism in pancreatic cancerCaleb Cheng, Jing Hu, Rahul Mannan, et al.
Biorxiv : the Preprint Server for Biology|April 2, 2024
<i>CDK12</i> Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.
Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.
Pageof 2